TY - JOUR
T1 - Prevalence and specificity of LKB1 genetic alterations in lung cancers
AU - Matsumoto, S.
AU - Iwakawa, R.
AU - Takahashi, K.
AU - Kohno, T.
AU - Nakanishi, Y.
AU - Matsuno, Y.
AU - Suzuki, K.
AU - Nakamoto, M.
AU - Shimizu, E.
AU - Minna, J. D.
AU - Yokota, J.
N1 - Funding Information:
This work was supported by Grants-in-Aid from the Ministry of Health, Labor and Welfare of Japan for the 3rd-term Comprehensive 10-year Strategy for Cancer Control and for Cancer Research (16-1), from the program for promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio), and from National Cancer Institute Lung Cancer SPORE (Grant Number: P50CA70907).
PY - 2007/8/30
Y1 - 2007/8/30
N2 - Germline LKB1 mutations cause Peutz-Jeghers syndrome, a hereditary disorder that predisposes to gastrointestinal hamartomatous polyposis and several types of malignant tumors. Somatic LKB1 alterations are rare in sporadic cancers, however, a few reports showed the presence of somatic alterations in a considerable fraction of lung cancers. To determine the prevalence and the specificity of LKB1 alterations in lung cancers, we examined a large number of lung cancer cell lines and lung adenocarcinoma (AdC) specimens for the alterations. LKB1 genetic alterations were frequently detected in the cell lines (21/70, 30%), especially in non-small cell lung cancers (NSCLCs) (20/51, 39%), and were significantly more frequent in cell lines with KRAS mutations. Point mutations were detected only in AdCs and large cell carcinomas, whereas homozygous deletions were detected in all histological types of lung cancer. Among lung AdC specimens, LKB1 mutations were found in seven (8%) of 91 male smokers but in none of 64 females and/or nonsmokers, and were significantly more frequent in poorly differentiated tumors. The difference in the frequency of LKB1 alterations between cell lines and tumor specimens was likely to be owing to masking of deletions by the contamination of noncancerous cells in the tumor specimens. These results indicate that somatic LKB1 genetic alterations preferentially occur in a subset of poorly differentiated lung AdCs that appear to correlate with smoking males.
AB - Germline LKB1 mutations cause Peutz-Jeghers syndrome, a hereditary disorder that predisposes to gastrointestinal hamartomatous polyposis and several types of malignant tumors. Somatic LKB1 alterations are rare in sporadic cancers, however, a few reports showed the presence of somatic alterations in a considerable fraction of lung cancers. To determine the prevalence and the specificity of LKB1 alterations in lung cancers, we examined a large number of lung cancer cell lines and lung adenocarcinoma (AdC) specimens for the alterations. LKB1 genetic alterations were frequently detected in the cell lines (21/70, 30%), especially in non-small cell lung cancers (NSCLCs) (20/51, 39%), and were significantly more frequent in cell lines with KRAS mutations. Point mutations were detected only in AdCs and large cell carcinomas, whereas homozygous deletions were detected in all histological types of lung cancer. Among lung AdC specimens, LKB1 mutations were found in seven (8%) of 91 male smokers but in none of 64 females and/or nonsmokers, and were significantly more frequent in poorly differentiated tumors. The difference in the frequency of LKB1 alterations between cell lines and tumor specimens was likely to be owing to masking of deletions by the contamination of noncancerous cells in the tumor specimens. These results indicate that somatic LKB1 genetic alterations preferentially occur in a subset of poorly differentiated lung AdCs that appear to correlate with smoking males.
KW - Deletion
KW - LKB1
KW - Lung cancer mutation
KW - Poor differentiation
KW - Smoking
UR - http://www.scopus.com/inward/record.url?scp=34748845413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34748845413&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1210418
DO - 10.1038/sj.onc.1210418
M3 - Article
C2 - 17384680
AN - SCOPUS:34748845413
SN - 0950-9232
VL - 26
SP - 5911
EP - 5918
JO - Oncogene
JF - Oncogene
IS - 40
ER -